Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance
08/19/2021 - 08:05 AM
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President, Finance, Michael Inbar. The grant was approved by a majority of the independent directors of the Company on July 27, 2021 as an inducement material to Mr. Inbar entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grant to Mr. Inbar consisted of an option to purchase up to 118,000 shares of common stock and a restricted stock unit award with respect to 59,000 shares of common stock. The option has a ten-year term and an exercise price of $2.51 per share, the closing price per share of Solid Biosciences’ common stock as reported by Nasdaq on August 16, 2021. The option and restricted stock unit award each vest in four equal installments on each one-year anniversary of Mr. Inbar’s employment start date until the fourth anniversary of Mr. Inbar’s start date, subject to Mr. Inbar’s continued service with the Company through the applicable vesting dates.
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.
Investor Contact :Clowie@solidbio.com
David CareyDavid.Carey@finnpartners.com
Media Contact :Erich.Sandoval@finnpartners.com
SLDB Rankings
#5151 Ranked by Stock Gains
SLDB Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
About SLDB
solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.
